Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis

2023-07 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis​
Frisch, E. S; Häusler, D. & Weber, M. S​ (2023) 
Neurology: Neuroimmunology & Neuroinflammation10(4) pp. e200114​.​ DOI: https://doi.org/10.1212/NXI.0000000000200114 

Documents & Media

Main article335.46 kBAdobe PDF

License

Published Version

Attribution-NonCommercial-NoDerivs 4.0 CC BY-NC-ND 4.0

Details

Authors
Frisch, Esther S; Häusler, Darius; Weber, Martin S
Abstract
Natalizumab (NTZ), a monoclonal antibody against very late antigen-4 (VLA-4), is one of the most efficient therapies to prevent acute relapses in multiple sclerosis (MS). VLA-4 is the key adhesion molecule for peripheral immune cells, especially lymphocytes to enter the CNS. While its blockade thus virtually abrogates CNS infiltration of these cells, long-term exposure to natalizumab may also affect immune cell function.
Issue Date
July-2023
Journal
Neurology: Neuroimmunology & Neuroinflammation 
Organization
Institut für Neuropathologie ; Klinik für Neurologie 
ISSN
2332-7812
eISSN
2332-7812
Language
English
Sponsor
Open-Access-Publikationsfonds 2023

Reference

Citations


Social Media